Loading…
Loading…
BVAXF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BVAXF and 80,000+ other tickers.
See exactly how BVAXF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BVAXF and 80,000+ other tickers.
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option. In the oncology space, BioVaxys is advancing BVX-0918A, a haptenized tumor cell vaccine designed for ovarian cancer, and BVX-0918C, aimed at cervical cancer. The company also has programs addressing Human Papillomavirus (HPV), such as…
Unique MRI Study Shows How the Combination Exerts its Effect VANCOUVER, BC – TheNewswire - May 1, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of a study that further validates the immune response mechanism from a combination of its maveropepimut-S (MVP-S) immunotherapeutic vaccine combined with a checkpoint inhibitor and low dose intermittent cyclophosphamide in ovarian cancer. Led by Dr Kimberly Brewer of the IWK Health Center and Associate Professor, Faculty of Medicine-Dalhousie University, the study is entitled “MRI of Combination Immunotherapy in an Epithelial Ovarian Cancer Preclinical Model” and is published in the April 2026 edition of Nature/NPJ Imaging.
VANCOUVER, BC, April 28 2026 - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). The Company announced on March 3, 2026 (the “ Default Announcement ”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, its related management's discussion and analysis, and the Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “ Annual Filings ”). Under National Instrument 51-102 - Continuous Disclosure Obligations , the Annual Filings were required to be made not later than February 28, 2026. As a result of the delay in filing the Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2026, its related management's discussion and analysis, and related filings (collectively, the “ Interim Filings ”). Under National Instrument 51-102, the Interim Filings were required to be made not later than April 1, 2026.
VANCOUVER, BC, April 27th, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0) today announced the acceptance of an abstract related to the PESCO study, an investigator-initiated, open-label, non-randomized phase 1B/2 trial to evaluate the safety and efficacy of combination of BioVaxys' MVP-S with pembrolizumab (Keytruda™) and cyclophosphamide in patients with recurrent epithelial ovarian cancer for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, May 29th-June 6th, 2026. With over 44,000 expected attendees, including oncologists, researchers, and pharmaceutical professionals, the ASCO Annual Meeting is a top-tier global oncology conference, and is recognized as one of the most significant, high-visibility events for clinical trials, research, and oncology innovation. All accepted ASCO abstracts are published online as a supplement to the Journal of Clinical Oncology (JCO),
VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). The Company announced on March 3, 2026 (the “ Default Announcement ”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “ Annual Filings ”). Under National Instrument 51-102 - Continuous Disclosure Obligations , the Annual Filings were required to be made not later than February 28, 2026. The Company is actively working with its auditor, Dale Matheson Carr-Hilton LaBonte LLP, to complete the Annual Filings, which will be filed as soon as possible. As previously stated, subject to current conditions remaining the same, the Company remains confident in its ability to complete the Annual Filings by April 28, 2026.
VANCOUVER, BC, March 31, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). The Company announced on March 3, 2026 (the “ Default Announcement ”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “ Annual Filings ”). Under National Instrument 51-102 - Continuous Disclosure Obligations , the Annual Filings were required to be made not later than February 28, 2026. The Company is actively working with its auditor, Dale Matheson Carr-Hilton LaBonte LLP, to complete the Annual Filings, which will be filed as soon as possible. As previously stated, subject to current conditions remaining the same, the Company remains confident in its ability to complete the Annual Filings by April 28, 2026.